📣 VC round data is live. Check it out!

DaVita Valuation Multiples

Discover DaVita's revenue and EBITDA valuation multiples, acquisitions, and investment history, alongside public comparables like Apollo Hospitals, Aier EYE Hospital Group, Encompass Health, Tenet Healthcare and more.

DaVita Overview

About DaVita

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.


Founded

1994

HQ

United States

Employees

78.0K

Website

davita.com

Financials (LTM)

Revenue: $14B
EBITDA: $3B

EV

$25B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

DaVita Financials

DaVita reported last 12-month revenue of $14B and EBITDA of $3B.

In the same LTM period, DaVita generated $4B in gross profit, $3B in EBITDA, and $887M in net income.

Revenue (LTM)


DaVita P&L

In the most recent fiscal year, DaVita reported revenue of $14B and EBITDA of $3B.

DaVita is profitable as of last fiscal year, with gross margin of 32%, EBITDA margin of 21%, and net margin of 6%.

See analyst estimates for DaVita
LTMLast FY202320242025202620272028
Revenue$14B$14B$12B$13B$14B
Gross Profit$4B$4B$4B$4B$4B
Gross Margin32%32%31%33%32%
EBITDA$3B$3B$2B$3B$3B
EBITDA Margin21%21%19%21%19%
EBIT Margin16%15%13%15%15%
Net Profit$887M$818M$692M$936M$747M
Net Margin6%6%6%7%5%
Net Debt-$10B---

Financial data powered by Morningstar, Inc.

DaVita Stock Performance

DaVita has current market cap of $12B, and enterprise value of $25B.

Market Cap Evolution


DaVita's stock price is $189.81.

DaVita share price decreased by 2.3% in the last 30 days, and increased by 33.2% in the last year.

DaVita has an EPS (earnings per share) of $12.74.

See more trading valuation data for DaVita
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$25B$12B-2.3%-2.3%23.5%33.2%$12.74

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

DaVita Valuation Multiples

DaVita trades at 1.8x EV/Revenue multiple, and 8.7x EV/EBITDA.

See NTM and 2027E valuation multiples for DaVita

EV / Revenue (LTM)


DaVita Financial Valuation Multiples

As of June 2, 2026, DaVita has market cap of $12B and EV of $25B.

DaVita has a P/E ratio of 13.7x.

LTMLast FY202320242025202620272028
EV/Revenue1.8x1.8x2.0x1.9x1.8x
EV/EBITDA8.7x8.8x10.7x9.1x9.4x
EV/EBIT11.5x11.8x15.5x12.7x12.3x
EV/Gross Profit5.5x5.6x6.5x5.9x5.6x
P/E13.7x14.9x17.6x13.0x16.3x
EV/FCF24.2x18.9x16.6x16.9x18.9x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified DaVita Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

DaVita Margins & Growth Rates

DaVita grew revenue by 3% and EBITDA by 4% in the last fiscal year.

In the most recent fiscal year, DaVita reported gross margin of 32%, EBITDA margin of 21%, and net margin of 6%.

See estimated margins and future growth rates for DaVita

DaVita Margins

Last FY202420252026202720282029
Gross Margin32%33%32%33%
EBITDA Margin21%21%19%21%
EBIT Margin15%15%15%16%
Net Margin6%7%5%7%
FCF Margin10%11%10%-

DaVita Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth3%6%6%3%
Gross Profit Growth4%10%4%4%
EBITDA Growth4%17%(3%)11%
EBIT Growth6%22%3%11%
Net Profit Growth20%35%(20%)32%
FCF Growth-(2%)(11%)-

Data powered by FactSet, Inc. and Morningstar, Inc.

DaVita Operational KPIs

DaVita's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.0M for the same period.

DaVita's Rule of 40 is 24% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

DaVita's Rule of X is 29% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for DaVita
LTMLast FY202320242025202620272028
Rule of 4024%24%---
Bessemer Rule of X29%29%---
Revenue per Employee-$0.2M---
Opex per Employee-$0.0M---
G&A Expenses to Revenue12%12%12%12%12%
Opex to Revenue-18%18%18%18%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Apollo Hospitals4.9x4.8x30.8x31.9x
Aier EYE Hospital Group3.9x3.7x13.3x12.8x
Encompass Health2.2x2.1x9.2x9.8x
Tenet Healthcare1.2x1.2x5.5x5.4x
Max Healthcare Institute11.2x10.4x36.9x35.5x
Mayapada Hospital66.9x-696.3x-
Rede D'Or São Luiz1.5x1.5x7.1x8.1x
Bangkok Dusit Medical Services2.5x2.5x10.5x10.5x

This data is available for Pro users. Sign up to see all DaVita competitors and their valuation data.

Start Free Trial

Acquisitions by DaVita

DaVita has acquired 5 companies to date.

Last acquisition by DaVita was on March 7th 2025. DaVita acquired Brasnefro for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by DaVita

Brasnefro
MedSleuth
Northwest Physicians Network
Purity Dialysis
Description
-
MedSleuth is a patient engagement platform based in the United States. It empowers individuals to research symptoms, track health data, and navigate care options through interactive tools and provider connections.
-
Purity Dialysis is a network of outpatient dialysis centers serving southeastern Wisconsin communities. Facilities in Brookfield, Fort Atkinson, Germantown, Menomonee Falls, Mukwonago, Oconomowoc, Watertown, and Waukesha offer hemodialysis and home peritoneal dialysis training. Staffed by nephrologists and technicians for ESRD patients.
HQ CountryBrazilUnited StatesUnited StatesUnited States
HQ City
-
San Francisco, CA
-
Milwaukee, WI
Deal Date7 Mar 202518 Jan 202228 Nov 20178 May 2017
Valuationundisclosedundisclosedundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DaVita acquisitions and their M&A valuation multiples.

Start Free Trial

Investments by DaVita

DaVita has invested in 2 companies to date.

Latest investment by DaVita was on September 4th 2024. DaVita invested in EGenesis in their $191M Series D round (EV/Revenue multiple available to Pro users).

See VC round multiples

Latest Investments by DaVita

EGenesis
CVRx
Description
eGenesis is a Cambridge-headquartered biotechnology company engineering xenotransplantation solutions. Utilizes CRISPR-based genome editing to produce human-compatible porcine organs, kidneys, and islet cells. Achieved FDA IND clearance for renal xenotransplant trials in 2024. Partners with United Therapeutics and JW Medical on clinical pathways to address organ shortages.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
HQ CountryUnited StatesUnited States
HQ City
-
Minneapolis, MN
Deal Date4 Sep 202430 Oct 2013
RoundSeries DSeries F
Raised$191M$12M
InvestorsAlta Partners; ARCH Venture Partners; DaVita; Eisai Innovation; Farallon Capital Management; Fresenius Medical Care; Khosla Ventures; Leaps by Bayer; Lux Capital; Natco Pharma; ParkwoodDaVita; Ysios Capital
Valuationundisclosedundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all DaVita investments and their VC round multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About DaVita

When was DaVita founded?DaVita was founded in 1994.
Where is DaVita headquartered?DaVita is headquartered in United States.
How many employees does DaVita have?As of today, DaVita has over 78K employees.
Who is the CEO of DaVita?DaVita's CEO is Javier J. Rodriguez.
Is DaVita publicly listed?Yes, DaVita is a public company listed on NYSE.
What is the stock symbol of DaVita?DaVita trades under DVA ticker.
When did DaVita go public?DaVita went public in 1995.
Who are competitors of DaVita?DaVita main competitors include Apollo Hospitals, Aier EYE Hospital Group, Encompass Health, Tenet Healthcare, Max Healthcare Institute, Mayapada Hospital, Rede D'Or São Luiz, Bangkok Dusit Medical Services, Universal Health Services, Fortis Healthcare.
What is the current market cap of DaVita?DaVita's current market cap is $12B.
What is the current revenue of DaVita?DaVita's last 12 months revenue is $14B.
What is the current revenue growth of DaVita?DaVita revenue growth (NTM/LTM) is 3%.
What is the current EV/Revenue multiple of DaVita?Current revenue multiple of DaVita is 1.8x.
What is the current EBITDA of DaVita?DaVita's last 12 months EBITDA is $3B.
What is DaVita's EBITDA margin?DaVita's last 12 months EBITDA margin is 21%.
What is the current EV/EBITDA multiple of DaVita?Current EBITDA multiple of DaVita is 8.7x.
What is the current FCF of DaVita?DaVita's last 12 months FCF is $1B.
What is DaVita's FCF margin?DaVita's last 12 months FCF margin is 7%.
What is the current EV/FCF multiple of DaVita?Current FCF multiple of DaVita is 24.2x.
How many companies DaVita has acquired to date?As of June 2026, DaVita has acquired 5 companies.
What was the largest acquisition by DaVita?None of the M&A deals DaVita has completed have disclosed valuations.
What companies DaVita acquired?DaVita acquired MedSleuth, Family Health Care of Central Florida, Brasnefro, Purity Dialysis, and Northwest Physicians Network.
In how many companies DaVita has invested to date?As of June 2026, DaVita has invested in 2 companies.
What was the last DaVita investment?On 4th September 2024 DaVita invested in EGenesis, participating in a $191M Series D round, alongside Alta Partners, ARCH Venture Partners, Eisai Innovation, Farallon Capital Management, Fresenius Medical Care, Khosla Ventures, Leaps by Bayer, Lux Capital, Natco Pharma, and Parkwood.
In what companies DaVita invested in?DaVita invested in EGenesis and CVRx.

See public comps similar to DaVita

Lists including DaVita

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial